FDA OKs First Drug Made to Reduce Excessive Sweating

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

The U.S. Food and Drug Administration has approved the first drug developed specifically to reduce excessive sweating, a common condition that can cause anxiety.

Dermira Inc. said Friday its Qbrexza (cue-BREX’-zah) was approved for excessive underarm sweating. The drug is inside a cloth wiped over the skin daily to block sweat glands from activating.

Dermira refused to disclose the price. Qbrexza will be available in October.

An estimated 15.3 million Americans have some form of excessive sweating, but only 1 in 4 get treatment. Current treatment options include Botox injections, surgery and off-label use of drugs that block the body’s chemical messengers.

Dermira said in one study, 53 percent of patients reported Qbrexza reduced sweat production by roughly half, versus 28 percent in a comparison group using a nonmedicated cloth.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.